Value of quantitative salivary gland scintigraphy in the early stage of Sjögren's syndrome
- PMID: 8587757
- DOI: 10.1097/00006231-199511000-00007
Value of quantitative salivary gland scintigraphy in the early stage of Sjögren's syndrome
Abstract
The aim of this study was to test the impact of quantitative salivary gland scintigraphy in patients with suspected Sjögren's syndrome. Thirteen patients with suspected Sjögren's syndrome were investigated. During clinical work-up, three had severe and four had mild Sjögren's syndrome, while six were normal. Quantitative salivary gland scintigraphy was performed using a standardized method. The normal data-base consisted of 172 patients without any evidence of salivary gland malfunction. Visual and quantitative comparisons of the patients' scintigrams were made. In the patients with severe Sjögren's syndrome, uptake was 0.10 +/- 0.04% and 0.09 +/- 0.03% in the parotid and submandibular glands respectively, confirming the visual diagnosis. In the patients without Sjögren's syndrome, concordance between the visual and quantitative evaluations could also be shown. In contrast, among the patients with mild Sjögren's syndrome, uptake was diminished (P < 0.05), amounting to 0.21 +/- 0.05% and 0.16 +/- 0.02% in the parotid and submandibular glands respectively, while visual analysis indicated normal parenchymatous function. In conclusion, quantitative salivary gland scintigraphy is essential for the reliable detection of parenchymatous malfunction at an early stage of Sjögren's syndrome, which may be missed by visual analysis alone.
Similar articles
-
Sjögren's syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography.J Nucl Med. 2000 Feb;41(2):257-62. J Nucl Med. 2000. PMID: 10688108
-
Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren's syndrome.J Nucl Med. 2001 Jan;42(1):38-43. J Nucl Med. 2001. PMID: 11197978
-
A quantitative index derived from 99mTc-pertechnetate scintigraphy to assist in the diagnosis of primary Sjögren's syndrome.Nuklearmedizin. 1992 Feb;31(1):3-6. Nuklearmedizin. 1992. PMID: 1313974
-
[Ultrasound diagnostics in Sjögren's syndrome].Z Rheumatol. 2017 Sep;76(7):589-594. doi: 10.1007/s00393-017-0305-5. Z Rheumatol. 2017. PMID: 28447158 Review. German.
-
Role of nuclear scintigraphy in the characterization and management of the salivary component of Sjögren's syndrome.Rheum Dis Clin North Am. 2008 Nov;34(4):973-86, ix. doi: 10.1016/j.rdc.2008.08.011. Rheum Dis Clin North Am. 2008. PMID: 18984416 Review.
Cited by
-
Correlations between histopathologic and scintigraphic parameters of salivary glands in patients with Sjögren's syndrome.Clin Rheumatol. 2012 Sep;31(9):1365-70. doi: 10.1007/s10067-012-2024-2. Epub 2012 Jun 26. Clin Rheumatol. 2012. PMID: 22733368
-
Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1778-85. doi: 10.1007/s00259-009-1368-6. Epub 2010 Feb 4. Eur J Nucl Med Mol Imaging. 2010. PMID: 20130857 Review.
-
Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren's Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications.J Clin Med. 2022 Jul 27;11(15):4368. doi: 10.3390/jcm11154368. J Clin Med. 2022. PMID: 35955984 Free PMC article.
-
Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.Strahlenther Onkol. 1999 Feb;175(2):57-61. doi: 10.1007/BF02753843. Strahlenther Onkol. 1999. PMID: 10065139 Clinical Trial.
-
Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.Thyroid. 2013 Nov;23(11):1445-51. doi: 10.1089/thy.2012.0243. Epub 2013 Jul 25. Thyroid. 2013. PMID: 23607283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical